KR20200083712A - Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use - Google Patents

Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use Download PDF

Info

Publication number
KR20200083712A
KR20200083712A KR1020180171721A KR20180171721A KR20200083712A KR 20200083712 A KR20200083712 A KR 20200083712A KR 1020180171721 A KR1020180171721 A KR 1020180171721A KR 20180171721 A KR20180171721 A KR 20180171721A KR 20200083712 A KR20200083712 A KR 20200083712A
Authority
KR
South Korea
Prior art keywords
extract
complex
soybean
bokbunja
active ingredient
Prior art date
Application number
KR1020180171721A
Other languages
Korean (ko)
Inventor
최정환
오병택
박정희
임정묵
이정호
임소연
김대건
박석원
Original Assignee
주식회사 이앤코리아
재단법인 순창군건강장수연구소
전북대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 이앤코리아, 재단법인 순창군건강장수연구소, 전북대학교산학협력단 filed Critical 주식회사 이앤코리아
Priority to KR1020180171721A priority Critical patent/KR20200083712A/en
Publication of KR20200083712A publication Critical patent/KR20200083712A/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065Microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/758Zanthoxylum, e.g. pricklyash
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10Preparation or pretreatment of starting material
    • A61K2236/19Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a cosmetic material composition containing a composite fermented extract of Rubus coreanus, soybeans, and Zanthoxylum schinifolium as an active ingredient. More specifically, the present invention relates to the cosmetic material composition including an active ingredient produced by fermenting a composite extract of Rubus coreanus, soybeans, and Zanthoxylum schinifolium having antioxidant, anti-inflammatory, and skin whitening effects. The composition produced according to the present invention and including the composite fermented extract of Rubus coreanus, soybeans, and Zanthoxylum schinifolium has excellent antioxidant, antiaging, anti-inflammatory, skin whitening, and wrinkle alleviating effects, thereby being capable of being used as a cosmetic material composition, a pharmaceutical composition, and a health food.

Description

복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물 및 이의 용도{COMPOSITION CONTAINING AN MIXED FERMENTATION EXTRACT OF RUBUS COREANUS, SOY BEAN AND ZANTHOXYLUM SCHINIFOLIUM AS AN ACTIVE INGREDIENT AND ITS USE}Cosmetic composition containing the compound fermented extract of soybean, soybean, and wild pepper as an active ingredient and its use{COMPOSITION CONTAINING AN MIXED FERMENTATION EXTRACT OF RUBUS COREANUS, SOY BEAN AND ZANTHOXYLUM SCHINIFOLIUM AS AN ACTIVE INGREDIENT AND ITS USE}

본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물에 대한 것이다. 보다 상세하게는, 본 발명은 항산화, 항염증, 피부 미백 및 주름 개선 효과를 나타내는 복분자, 대두 및 산초의 복합 추출물을 발효시켜 제조된 유효성분을 포함하는 화장료 조성물에 대한 것이다. The present invention relates to a cosmetic composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient. In more detail, the present invention relates to a cosmetic composition comprising an active ingredient prepared by fermenting a complex extract of bokbunja, soybean and sancho, which has antioxidant, anti-inflammatory, skin whitening and wrinkle improvement effects.

천연물로부터 생리활성 물질에 관한 연구가 활발히 진행되고 있으며, 질병에 대한 치료 및 예방제 또는 건강보조제로서 식물 자원이 널리 이용되고 있다.Researches on bioactive substances from natural products are being actively conducted, and plant resources are widely used as treatment and preventive agents or health supplements for diseases.

피부 노화는, 시간이 경과함에 따라 기관과 동반하여 피부의 구조와 기능이 지속적으로 감퇴되어지는 내인성 노화와 장기간에 걸친 태양 광선의 노출로 인한 피부 조직의 변화인 외인성 노화가 있다. 이러한 노화 과정으로 피부가 건조해지며, 주름이 생기고 피부는 탄력을 잃게 된다.Skin aging includes endogenous aging, in which the structure and function of the skin are continuously reduced along with organs over time, and exogenous aging, which is a change in skin tissue due to prolonged exposure to sunlight. Through this aging process, the skin becomes dry, wrinkles are formed, and the skin loses elasticity.

피부 노화에 관한 연구에서 가장 중요하게 다루어지는 것은 자유 라디칼(free radical)과 활성 산소종(reactive oxygen species)이다. 이들은 자연적으로 생체 내에서 만들어지기도 하지만 공해, 태양 자외선, 화학 산화제 및 미생물 등에 의해 발생된다. 이 때 발생된 자유 전자기나 활성 산소종은 피부 세포에 산화적 스트레스를 가하게 되고, 이러한 과정에서 생긴 물질은 멜라닌과 주름 생성의 원인물질로 여겨진다.The most important topics in skin aging research are free radicals and reactive oxygen species. They are naturally produced in vivo, but they are generated by pollution, solar ultraviolet rays, chemical oxidizing agents and microorganisms. The free electromagnetic or free radicals generated at this time exert oxidative stress on the skin cells, and the material produced in this process is considered to be the cause of melanin and wrinkles.

이때 발생되어진 자유 전자나 활성 산소종은 피부세포에 산화적 스트레스를 가하게 되고, 이러한 과정에서 생긴 물질은 멜라닌과 주름 생성의 원인 물질로 여겨진다.The free electrons or free radicals generated at this time exert oxidative stress on the skin cells, and the material produced in this process is considered to be the source of melanin and wrinkles.

이들 활성 산소종은 효소적, 비효소적 항산화제로 이루어진 피부 항산화 방어막을 붕괴시키고 생체 분자의 산화적 변형, 피부 장벽의 손상과 결합 조직인 콜라겐, 히아루론산 등의 사슬 절단 및 비정상적인 교차결합에 의한 주름생성 등 피부 노화를 가속시킨다.These free radicals disintegrate the skin antioxidant barrier made of enzymatic and non-enzymatic antioxidants, oxidative modification of biomolecules, damage to skin barrier and chain breakage of connective tissue such as collagen and hyaluronic acid, and wrinkle formation by abnormal cross-linking, etc. Accelerates skin aging

결과적으로 피부 노화 방지를 위해서는 과잉의 활성 산소종 생성을 억제하고 또한 생성된 활성 산소를 효율적으로 제거할 수 있어야 한다. 또한 피부 주름을 일으키는 효소들의 억제와 색소 침착을 진행하는 효소 활성 억제 등에 관한 연구가 필요하다. As a result, in order to prevent skin aging, it is necessary to suppress the generation of excess free radicals and to effectively remove the free radicals produced. In addition, studies on the inhibition of enzymes that cause skin wrinkles and the inhibition of enzyme activity that progresses pigmentation are needed.

한편, 멜라닌 생성 혹은 멜라노사이트의 증식에 의해 야기되는 색소 침착은 다양한 방법으로 억제가 가능하다. 일반적으로는 멜라닌 합성의 중요한 효소인 티로시나제(Tyrosinase) 활성 억제, 멜라노사이트의 기능 감소, 자동산화 반응의 억제를 통한 멜라닌 생성의 감소, 홍반과 같은 염증반응 억제등 다양한 경로를 이용할 수 있다.On the other hand, pigmentation caused by melanin production or proliferation of melanocytes can be suppressed in various ways. In general, various pathways such as inhibition of tyrosinase activity, an important enzyme for melanin synthesis, reduction of melanocyte function, reduction of melanin production through inhibition of an automatic oxidation reaction, and inhibition of inflammatory reactions such as erythema can be used.

결과적으로 피부노화 방지를 위해서는 과잉의 활성 산소종 생성을 억제하고 또한 생성된 활성산소를 효율적으로 제거할 수 있어야 하며, 피부의 주름을 일으키는 효소들의 억제, 색소침착을 진행하는 효소의 활성억제 등에 관한 연구가 필요하다. As a result, in order to prevent skin aging, it is necessary to suppress the generation of excess free radicals and to effectively remove the generated free radicals, and to suppress the enzymes that cause wrinkles on the skin and to inhibit the activity of enzymes that undergo pigmentation. Research is needed.

이와 관련하여, 피부노화 및 미백 관련해서 식물을 이용한 연구가 시행되어 왔다.In this regard, research using plants has been conducted in relation to skin aging and whitening.

복분자(Rubus coreauns)는 장미과(Rosaceae)에 속하는 복분자딸기의 열매를 일컫는 생약명으로, 복분자를 먹으면 요강이 소변 줄기에 뒤집어진다고 하여 붙은 이름이다. 복분자는 총당(17.3%), 환원당(8.6%), 조단백질(10.6%), 조회분(4.5%), 조지방(3.1%) 및 조섬유(3.9%)와 같은 성분을 함유하고 있으며, 아밀알코올을 포함하는 11종의 알코올류, 발레르산을 포함하는 산(acid)류, 헥산알을 포함하는 20종의 카보닐류, 2-헵타논을 포함하는 5종류의 하이드로카본, 및 메틸팔미트산염을 포함하는 3종류의 에스테르류의 향기성분을 함유하고 있다. 또한 폴리페놀(polyphenol)을 다량 함유하고 있어, 항암효과, 콜레스테롤의 저하, 고혈압이나 동맥경화의 억제, 과산화지질의 생성을 막아 노화의 예방, 혈청중 지질농도의 저하, 중성지질의 생성 억제에 의해 비만 방지 및 모세혈관의 저항력 증진 효과가 있는 것으로 보고되고 있다.Rubus coreauns is a medicinal name that refers to the fruit of a bokbunja strawberry belonging to the family Rosaceae. Bokbunja contains ingredients such as total sugar (17.3%), reduced sugar (8.6%), crude protein (10.6%), crude ash (4.5%), crude fat (3.1%) and crude fiber (3.9%), and contains amyl alcohol It contains 11 kinds of alcohols, acids containing valeric acid, 20 kinds of carbonyls including hexanal, 5 kinds of hydrocarbons including 2-heptanone, and methyl palmitate. Contains three types of ester fragrance components. In addition, since it contains a large amount of polyphenols, it has anti-cancer effects, lowering cholesterol, suppressing hypertension or arteriosclerosis, preventing the formation of lipid peroxide, preventing aging, lowering the lipid concentration in serum, and suppressing the production of neutral lipids. It has been reported to have an effect of preventing and enhancing capillary resistance.

대두(soybean)는 건물량 중 약 40%가 단백질로 구성되어 있고, 필수 아미노산이 풍부하여 우리나라에서는 전통적으로 단백질의 급원으로 사용되어 왔다. 다른 곡류의 단백질량이 보통 8~12%이고, 다른 콩과 식품의 단백질량이 20~30% 정도인 것을 고려하면, 대두의 단백질 구성은 매우 높은 수준이다. 또한, 대두에는 최근 생리활성 기능이 보고된 이소플라본(isoflavones) 및 피트산(phytic acid) 등이 풍부하며, 전 세계적으로 가공식품의 원료로 널리 사용되고 있다.Soybeans are traditionally used as a source of protein in Korea because about 40% of the amount of building is composed of protein and rich in essential amino acids. Considering that the amount of protein in other cereals is usually 8~12% and that of other legumes is about 20~30%, the protein composition of soybean is very high. In addition, soybean is rich in isoflavones and phytic acid, which have recently been reported to have bioactive functions, and are widely used as raw materials for processed foods worldwide.

산초(Zanthoxylum Schinifolium)는 쌍떡잎식물 쥐손이풀목 운향과의 낙엽관목으로 산지에서 자란다. 높이는 3m이고 잔가지는 가시가 있으며 붉은빛이 도는 갈색이다. 잎은 어긋나고 13-21개의 작은 잎으로 구성된 깃꼴겹잎이다. 작은 잎은 길이 1-5cm의 넓은 바소꼴이며 양끝이 좁고 가장자리에 물결 모양의 톱니와 더불어 투명한 유점이 있다. 산초는 잎을 따서 생으로 사용하거나, 열매껍질을 벗겨 말린 후 달이거나 농축해서 사용한다. 산초 열매는 소화불량, 식체, 위하수, 위확장, 구토, 이질, 설사, 신경쇠약, 기침, 회충 구제 등에 효능이 있다. 요리에는 후추와 비슷한 방법으로 사용된다.Sancho ( Zanthoxylum Schinifolium ) is a deciduous shrub with the dicotyledonous family of the Euphorbia musculus and grows in the mountains. The height is 3m, the twigs are thorny and reddish brown. The leaves are misaligned, composed of 13-21 small leaves. The small leaves are 1-5cm long, lanceolate, narrow at both ends, and have wavy teeth on the edges, with transparent spots. Sancho is used by picking leaves and using it raw or peeled and dried before being dried or concentrated. Sancho fruit is effective for indigestion, plant, stomach and sewage, gastric expansion, vomiting, dysentery, diarrhea, nervous breakdown, coughing, and roundworm remedies. It is used in a similar way to pepper.

이러한 복분자 발효 추출물의 심혈관 질환 치료 용도(특허문헌 1 참조), 대두 발효 추출물의 고지혈증 치료 용도(특허문헌 2 참조) 또는 산초 유래의 산초유를 포함하는 조성물의 아토피 피부 개선 용도(특허문헌 3 참조)에 대한 연구는 진행되었으나 항산화, 항노화, 항염증 및 미백 효능에 대한 연구, 또는 복분자, 대두 및 산초 복합 발효 추출물에 관련된 연구는 진행되지 않은 상황이다. Cardiovascular disease treatment use of the fermentation extract of the bimolecular molecule (refer to patent document 1), hyperlipidemia treatment use of soybean fermentation extract (refer to patent document 2), or atopy skin improvement use of a composition containing wild botanical oil derived from wild herb (see patent document 3) Studies have been conducted, but studies on antioxidant, anti-aging, anti-inflammatory and whitening efficacy, or studies related to bokbunja, soybean, and herbaceous complex fermentation extract have not been conducted.

이에 본 발명자들은 복분자, 대두 및 산초의 복합 발효 추출물을 이용한 연구를 수행하여 상기 복합 발효 추출물의 항산화, 항염증 및 미백 효능을 확인하여 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming the antioxidant, anti-inflammatory, and whitening efficacy of the complex fermentation extract by conducting a study using the complex fermentation extract of bokbunja, soybean, and green pepper.

한국등록특허공보 제10-0862610호Korean Registered Patent Publication No. 10-0862610 한국등록특허공보 제10-0656241호Korean Registered Patent Publication No. 10-0656241 한국등록특허공보 제10-1056475호Korean Registered Patent Publication No. 10-1056475

본 발명의 목적은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물을 제공하기 위한 것이다.An object of the present invention is to provide a cosmetic composition containing a complex fermentation extract of bokbunja, soybean and sancho as an active ingredient.

본 발명의 다른 목적은 복분자, 대두 및 산초의 복합 추출물을 발효시켜 항산화, 항노화, 항염증 및 피부 미백 효과가 있는 유효 성분을 제조하는 방법 및 상기 유효성분을 포함하는 화장료 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preparing an active ingredient having anti-oxidation, anti-aging, anti-inflammatory and skin whitening effects by fermenting a complex extract of bokbunja, soybean and sancho, and a cosmetic composition comprising the active ingredient .

본 발명의 또 다른 목적은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화, 항염증 및 피부 미백 효과가 있는 건강 식품을 제공하기 위한 것이다.Another object of the present invention is to provide a health food having antioxidant, anti-aging, anti-inflammatory, and skin whitening effects containing a complex fermented extract of bokbunja, soybean, and wild pepper as an active ingredient.

본 발명은 복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition containing a complex fermentation extract of bokbunja, soybean and sancho as an active ingredient.

상기 화장료 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 있을 수 있다.The cosmetic composition may have antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects.

상기 복분자, 대두 및 산초의 복합 추출물은 복분자, 대두 및 산초를 1:1:1 의 중량비로 혼합하여 제조할 수 있다. 복합 추출물 내 복분자, 대두 및 산초의 중량비가 1:1:1 범위를 벗어나는 경우, 발효시 발효 효율이 낮고 발효에 의해 제조된 복합 발효 추출물의 항염증 활성, 항산화 활성, 미백 효능 및 주름 개선 효능이 낮아서 비효율적이다.The complex extract of the bokbunja, soybean and sancho can be prepared by mixing bokbunja, soybean and sancho in a weight ratio of 1:1:1. When the weight ratio of bokbunja, soybean, and pepper in the complex extract is outside the 1:1:1 range, the fermentation efficiency during fermentation is low and the anti-inflammatory activity, antioxidant activity, whitening effect and wrinkle improvement effect of the complex fermentation extract prepared by fermentation Low and inefficient.

상기 유효성분은 복분자, 대두 및 산초의 복합 추출물을 유산균을 발효시켜 제조될 수 있고, 상기 유산균은 락토바실러스 균주 중 어느 하나일 수 있으며, 바람직하게는 페디오코커스(Pediococcus) 균주일 수 있으며, 가장 바람직하게는 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP)이다. The active ingredient may be prepared by fermenting lactic acid bacteria with a complex extract of bokbunja, soybean, and sancho, and the lactic acid bacteria may be any of the Lactobacillus strains, preferably Pediococcus strains, Preferably Pediococcus pentosaceus B1, accession number KACC 81067BP).

상기 발효는 다양한 페디오코커스(Pediococcus) 균주를 복합 추출물 시료를 기준으로 균주액을 7 중량% 비율로 사용하여 실시할 수 있는데, 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP) 균주를 사용하는 것이 바람직하다. 페디오코커스 펜토사세우스(Pediococcus pentosaceus B1, 기탁번호 KACC 81067BP) 이외의 균주를 사용하는 경우에는 발효 효율이 낮아서 비효율적이다. 또한, 균주액의 비율을 7 중량% 미만 또는 7 중량%를 초과하여 사용하면 발효 효율이 낮아서 비효율적이다.The fermentation may be carried out using various strains of Pediococcus strains based on a composite extract sample in a ratio of 7% by weight, Pediococcus pentosaceus B1, accession number KACC 81067BP It is preferred to use strains. When a strain other than Pediococcus pentosaceus B1 (Accession No. KACC 81067BP) is used, fermentation efficiency is low and thus inefficient. In addition, when the proportion of the strain solution is used in an amount of less than 7% by weight or more than 7% by weight, fermentation efficiency is low and thus inefficient.

상기 발효는 37℃에서 2 내지 7일간 실시할 수 있는데, 37℃ 보다 낮은 온도에서 발효하는 경우 발효 효율이 낮고, 2일 미만 또는 7일을 초과하여 발효하는 경우에는 발효 효율이 낮아서 비효율적이다.The fermentation can be carried out at 37°C for 2 to 7 days. When fermenting at a temperature lower than 37°C, the fermentation efficiency is low, and when fermenting for less than 2 days or for more than 7 days, the fermentation efficiency is low, which is inefficient.

본 발명에 따른 유효성분인 복분자, 대두 및 산초의 복합 발효 추출물은 화장료 조성물 전체에 대하여 50 내지 600 ㎍/mL로 포함될 수 있고, 보다 바람직하게는 100 내지 500 ㎍/mL로 포함될 수 있으며, 가장 바람직하게는 200 내지 300 ㎍/mL로 포함될 수 있다.The complex fermentation extract of the active ingredient according to the present invention, bokbunja, soybean and sancho, may be included at 50 to 600 µg/mL, more preferably 100 to 500 µg/mL, most preferably It may be included at 200 to 300 μg/mL.

상기 복분자, 대두 및 산초 복합 발효 추출물의 함량이 100 ㎍/mL 미만인 경우에는 미백 효능, 항산화 활성, 항노화 활성 및 항염증 활성이 나타나지 않을 수 있으며, 500 ㎍/mL 초과하는 경우에는 함유량 증가에 대한 효과 증대 정도가 미미할 수 있고 세포 독성이 강해서 경제적이지도 못하다.When the content of the complex molecule, soybean and wild-fermented fermentation extract is less than 100 µg/mL, the whitening efficacy, antioxidant activity, anti-aging activity and anti-inflammatory activity may not be exhibited, and when it exceeds 500 µg/mL, The degree of increase in effect may be negligible, and it is not economical due to strong cytotoxicity.

상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 팩, 파운데이션, 젤, 연고 또는 스프레이로 구성된 군으로부터 선택될 수 있으나. 반드시 이로 한정되는 것은 아니다.The cosmetic composition may be selected from the group consisting of lotion, essence, lotion, cream, pack, foundation, gel, ointment or spray. It is not necessarily limited to this.

또한, 상기 화장료 조성물은 본 발명의 복분자, 대두 및 산초 복합 발효 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항노화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic composition is a fat substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an anti-aging agent, a suspending agent, a stabilizing agent, a foaming agent, in addition to the complex fermented extract of the compound of the present invention, soybean and pepper ), fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipids It may contain adjuvants commonly used in the cosmetic field, such as vesicles or any other ingredients commonly used in cosmetics.

본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화 효과 및 항염증 효과가 있는 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition having an antioxidant, anti-aging effect and anti-inflammatory effect, which contains a complex fermented extract of bokbunja, soybean and wild pepper as an active ingredient.

본 발명의 약학적 조성물은 통상적으로 사용되는 부형제, 붕해제, 감미제, 활택제, 향미제 등을 추가로 포함할 수 있으며, 통상적인 방법에 의해 정제, 캅셀제, 산제, 과립제, 현탁제, 유제, 시럽제, 기타 액제로 제형화될 수 있다. 구체적으로 본 발명의 약학적 조성물은 경구 투여용 제형, 예를 들면 정제, 트로치제(troches), 로젠지(lozenge), 수용성 또는 우성현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)로 제제화된다. 정제 및 캡슐 등의 제형으로 제제하기 위해 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴, 셀롤로오스 또는 젤라틴과 같은 결합제, 디칼슘 포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕해제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아릴푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유된다. 캡슐제형의 경우는 상기에서 언급한 물질 이외에도 지방유와 같은 액체 담체를 함유한다.The pharmaceutical composition of the present invention may further include commonly used excipients, disintegrants, sweeteners, lubricants, flavoring agents, and the like, and tablets, capsules, powders, granules, suspensions, emulsions, by conventional methods, It can be formulated as a syrup, other liquid. Specifically, the pharmaceutical composition of the present invention may be formulated for oral administration, for example, tablets, troches, lozenges, water-soluble or dominant suspensions, preparation powders or granules, emulsions, hard or soft capsules, syrups or It is formulated as elixirs. Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, stearic acid for formulation into tablets and capsules Contains lubricants such as magnesium, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax. In the case of capsule formulations, in addition to the above-mentioned substances, a liquid carrier such as fatty oil is contained.

또한, 본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 비경구 투여시 피하주사, 정맥주사, 근육내 주사 또는 흉부내 주사 주입방식을 선택하는 것이 바람직하다. 비경구 투여용 제형으로 제제화하기 위해서는 본 발명의 센티페드그라스 추출물, 이의 분획물 또는 분획물로부터 분리한 활성분획을 안정제 또는 완충제와 함께 물에서 혼합하여 현탁액으로 제조하고 이를 앰플 또는 바이알의 단위 투여형으로 제제한다.In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally, it is preferable to select a subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method when parenteral administration. In order to formulate a formulation for parenteral administration, the centifedgrass extract of the present invention, the fraction or its active fraction separated from the fraction is mixed with water with a stabilizer or buffer in a suspension to prepare a suspension and prepared as a unit dosage form of ampoules or vials do.

본 발명에 따른 유효성분의 투여량은 체내에서 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 상태, 치료할 질병의 중증 정도에 따라 적절히 선택되나, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1 ㎏당 본 발명의 추출물을 0.0001 ~ 500 ㎎의 양으로 1회 내지 수회 나누어 투여할 수 있으며, 0.001 ~ 100 ㎎의 양으로 투여하는 것이 바람직하다.The dosage of the active ingredient according to the present invention is appropriately selected according to the absorption of the active ingredient in the body, the rate of inactivation and excretion rate, the patient's age, sex and condition, and severity of the disease to be treated, but in the case of oral dosage forms, in general The extract of the present invention per kg of body weight per day can be administered to an adult once or several times in an amount of 0.0001 to 500 mg, preferably in an amount of 0.001 to 100 mg.

또한, 본 발명은 복분자, 대두 및 산초 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 있는 건강 식품을 제공한다.In addition, the present invention provides a healthy food having antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects containing the complex fermented extract of bokbunja, soybean and wild pepper as an active ingredient.

본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 우수하므로 건강 식품으로서 유용하게 사용될 수 있다.The compound of the present invention, the complex fermentation extract of soybean and wild pepper, has excellent antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects, and thus can be usefully used as a health food.

본 발명의 건강식품은 복분자, 대두 및 산초 복합 발효 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The health food of the present invention may be added as a complex fermented extract of bokbunja, soybean, and herb, or may be used together with other foods or food ingredients, and may be suitably used according to a conventional method.

상기 식품의 종류에는 특별한 제한은 없다. 상기 복분자, 대두 및 산초 복합 발효 추출물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no particular restrictions on the type of food. Examples of foods to which the complex fermented soybean, soybean, and wild pepper complex fermentation extracts can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, and various soups , Beverages, teas, drinks, alcoholic beverages, and vitamin complexes, and includes all healthy foods in the usual sense.

본 발명의 건강 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 0.01 ~0.04 g, 바람직하게는 약 0.02 ~ 0.03 g 이다.The healthy beverage composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional components, like a conventional beverage. The aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, synthetic sweeteners such as saccharin and aspartame can be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 ml of the composition of the present invention, preferably about 0.02 to 0.03 g.

상기 외에 본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the complex fermented extract of the present invention, soybean and pepper, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers , Preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like.

그 밖에 본 발명의 복분자, 대두 및 산초 복합 발효 추출물은 천연 과일주스, 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the complex fermented extract of the compound of the present invention, soybean and pepper, may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These ingredients can be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

본 발명에 따라 제조된 복분자, 대두 및 산초의 복합 발효 추출물을 포함하는 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 효과가 우수하여 화장료 조성물, 약학적 조성물 및 건강 식품으로 이용할 수 있다.The composition comprising a complex fermented extract of bokbunja, soybean, and green pepper prepared according to the present invention has excellent antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement effects, and can be used as a cosmetic composition, pharmaceutical composition, and health food .

도 1은 복분자, 대두 및 산초의 복합 발효 추출물의 제조 과정을 나타낸 것이다.
도 2는 본 발명에서 사용한 발효 균주인 페디오코커스 펜토사세우스(Pediococcus pentosaceus) B1의 계통도에 관한 것이다.
도 3은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 제조 과정에서 발효 전 및 발효 후의 항산화 활성을 측정한 결과에 관한 것이다.
도 4는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 세포 독성을 측정한 결과에 관한 것이다.
도 5는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 NO(Nitric Oxide) 저해 활성을 측정한 결과에 관한 것이다.
도 6은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 항염증 저해 활성을 측정한 결과에 관한 것이다.
도 7은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 티로시나아제 저해 활성을 측정한 결과에 관한 것이다.
도 8은 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 멜라닌 생성 억제 활성을 측정한 결과에 관한 것이다.
도 9는 본 발명에 따른 복분자, 대두 및 산초의 복합 발효 추출물의 콜라겐 생성 활성을 측정한 결과에 관한 것이다.
Figure 1 shows the manufacturing process of the complex fermentation extract of bokbunja, soybean and sancho.
Figure 2 relates to the phylogenetic strain used in the present invention Pediococcus pentosaceus ( Pediococcus pentosaceus ) B1 is a schematic diagram.
Figure 3 relates to the results of measuring the antioxidant activity before and after fermentation in the process of preparing a complex fermentation extract of bokbunja, soybean and sancho according to the present invention.
Figure 4 relates to the results of measuring the cytotoxicity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 5 relates to the results of measuring the NO (Nitric Oxide) inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 6 relates to the results of measuring the anti-inflammatory inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 7 relates to the results of measuring the tyrosinase inhibitory activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.
Figure 8 relates to the results of measuring the melanin production inhibitory activity of the complex fermentation extract of bokbunja, soybean and sancho according to the present invention.
Figure 9 relates to the results of measuring the collagen production activity of the complex fermentation extract of bokbunja, soybean and wild pepper according to the present invention.

이하, 본 발명에 대하여 실시예 및 실험예를 통하여 보다 상세히 설명하나, 이들이 본 발명의 범위를 제한하는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples and experimental examples, but they do not limit the scope of the present invention.

실시예 1. 복합 발효 추출물 제조Example 1. Preparation of complex fermentation extract

1.1 복합 추출물 제조1.1 Preparation of complex extracts

복분자 열매 및 대두를 수확하여 세척하고, 동결 건조 후 150 mesh 이상으로 파쇄하였다. 상기 파쇄된 건조 복분자 분말. 대두 분말 및 산초 열매를 200 mesh로 체를 쳐서 분말의 입자를 균일하게 통일한 후 1: 1: 1 중량비로 혼합한 후, 증류수를 첨가하고, pH 6.5로 조정하였다.After harvesting and washing the bokbunja fruit and soybean, lyophilized and crushed to 150 mesh or more. The crushed dry bokbunja powder. Sieve soybean powder and peppercorns were sifted with a 200 mesh to uniformly unify the particles of the powder, and then mixed in a 1: 1 weight ratio, distilled water was added, and the pH was adjusted to 6.5.

pH를 조절한 복합 혼합물은 121℃에서 15분간 멸균을 실시하여 복분자, 대두 및 산초의 복합 추출물 시료를 제조하였다(도 1 참조).The pH-controlled composite mixture was sterilized at 121° C. for 15 minutes to prepare a composite extract sample of bokbunja, soybean, and green pepper (see FIG. 1 ).

1.2 발효 균주 제조 1.2 Preparation of fermented strains

유산균 페디오코커스 펜토사세우스(Pediococcus pentosaceus) B1(도 2 및 기탁증 참조)을 MRS 배지에 접종하여 37℃에서 24시간 배양하였다. 배양된 균주는 3,000 rpm, 4oC 조건에서 15분간 원심분리를 실시하여 균체를 회수한 후, 상기 균체는 인산염 완충액(Phosphate buffer solution)으로 3회 세척을 실시하였다. 세척된 균체는 인산염 완충액을 사용하여 O.D(Optical Density) 1.0의 균주액을 제조하였다(도 1 참조).Lactic acid bacteria Pediococcus pentosaceus B1 (see FIG. 2 and deposit) was inoculated in MRS medium and cultured at 37° C. for 24 hours. The cultured strain was centrifuged at 3,000 rpm, 4 o C for 15 minutes to recover the cells, and the cells were washed three times with a phosphate buffer solution. For the washed cells, a strain solution of OD (Optical Density) 1.0 was prepared using a phosphate buffer (see FIG. 1).

1.3 복합 발효 추출물 제조1.3 Preparation of complex fermented extracts

실시예 1.1에 따른 복합 추출물 시료 전체를 기준으로 실시예 1.2에 따른 균주액을 5 중량% 비율로 접종하였다. The strain solution according to Example 1.2 was inoculated at a ratio of 5% by weight based on the entire sample of the composite extract according to Example 1.1.

접종 후에, 37℃에서 5일간 발효시켜 발효물을 제조하였다. 상기 발효물에 대하여 20% 에탄올을 추출 용매로 사용하여 5시간 추출을 실시하여 추출물을 제조하였다. 상기 추출물 내 고형물을 완전히 제거한 후 동결 건조를 통해 복합 발효 추출물을 완성하였다(도 1 참조). After inoculation, fermentation was prepared by fermenting at 37°C for 5 days. The fermented product was extracted by performing extraction for 5 hours using 20% ethanol as an extraction solvent. After completely removing the solids in the extract, the complex fermentation extract was completed through freeze drying (see FIG. 1 ).

실시예 2. 세포 독성 측정Example 2. Cytotoxicity measurement

실험에 사용된 세포에 대한 독성을 평가하기 위하여 MTT assay에 따라 세포생존율을 평가하였다. 계대 배양된 Raw 264.7 cell을 DMEM 배지를 사용하여 96-well plate에 1×105 cell/well씩 분주하여 37℃, 5% CO2 incubator에서 24 시간동안 배양하였다. 배양 후 세포 외 배지를 제거한 후 추출물을 농도별로 조성한 DMEM 용액을 100 ㎕ 처리한 후 37℃, 5% CO2 incubator에서 24 시간동안 반응시켰다. 대조군으로는 시료를 처리하지 않은 DMEM 용액을 처리하여 동일한 방법으로 실험을 진행하였다. 반응이 끝난 후 잔류 배지를 제거하고 5 ㎎/㎖ MTT (3-(4,5-dimethylthi azol-2-yl) -2,5-diphenyltetrazolium bromide) 용액을 well 당 50 ㎕ 씩 처리하여 37℃에서 4 h 반응시켰다. 이후 MTT 용액 제거하고 37℃에서 30 분간 건조과정을 진행하였으며, DMSO(dimethyl sulfoxide) 용액을 100 ㎕ 첨가하여 생성된 formazan을 완전히 용해시킨 후 microplate reader를 사용하여 550 nm 파장에서 흡광도를 측정하였다. 대조군으로는 시료를 처리하지 않은 세포의 흡광도를 분석하여 사용하였으며, 대조군의 흡광도를 100% 기준으로 처리구의 흡광도를 백분율로 계산하여 세포의 생존율을 환산하였다.In order to evaluate the toxicity to the cells used in the experiment, the cell viability was evaluated according to the MTT assay. Passage-cultured Raw 264.7 cells were dispensed 1×10 5 cells/well in 96-well plates using DMEM medium, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After incubation, the extracellular medium was removed, and then 100 µl of the DMEM solution composed of extracts by concentration was treated and reacted at 37° C. in a 5% CO 2 incubator for 24 hours. As a control, an experiment was conducted in the same way by treating a DMEM solution that was not treated with a sample. After the reaction was completed, the residual medium was removed and 50 µl/well of 5 mg/ml MTT (3-(4,5-dimethylthi azol-2-yl) -2,5-diphenyltetrazolium bromide) solution was treated at 37°C and 4 h reacted. Thereafter, the MTT solution was removed, and the drying process was performed at 37°C for 30 minutes, and 100 μl of DMSO (dimethyl sulfoxide) solution was added to completely dissolve the formazan, and absorbance was measured at a wavelength of 550 nm using a microplate reader. As a control, the absorbance of cells not treated with a sample was analyzed and used, and the absorbance of the treatment group was calculated as a percentage based on 100% of the control, and the cell viability was calculated.

농도
(㎍/㎖)
density
(Μg/ml)
세포 생존율(Cell viability, %)Cell viability (%)
복합 추출물
(complex extract)
Complex extract
(complex extract)
발효 복합 추출물
(Fermented complex extract)
Fermentation complex extract
(Fermented complex extract)
5050 98.63±1.1298.63±1.12 109.00±2.08109.00±2.08 100100 94.39±2.8194.39±2.81 107.90±1.35107.90±1.35 200200 86.75±2.0386.75±2.03 102.55±2.03102.55±2.03 300300 88.97±2.5688.97±2.56 100.47±1.26100.47±1.26 400400 86.91±2.9786.91±2.97 98.48±1.3898.48±1.38 500500 86.80±0.8886.80±0.88 96.26±1.1496.26±1.14 600600 62.99±1.7662.99±1.76 81.30±1.6481.30±1.64

세포 생존율을 측정한 결과, 복합 발효 추출물은 발효를 실시하지 않은 복합 추출물에 비해 세포 독성이 낮음을 확인하였다(표 1 및 도 3 참조).As a result of measuring cell viability, it was confirmed that the complex fermentation extract had lower cytotoxicity than the complex extract without fermentation (see Table 1 and FIG. 3).

실시예 3. 항산화 활성 측정Example 3. Measurement of antioxidant activity

3.1 DPPH 소거 활성3.1 DPPH scavenging activity

자유라디칼은 노화, 특히 피부 노화의 원인 물질로 알려진 것이다. 자유 라디칼 소거 활성 측정을 위해 메탄올을 사용하여 0.2 mM DPPH(2,2-Diphenyl-1-picryl-hydrazyl) 용액을 제조한 이후 각 농도별로 조성된 추출물과 혼합하였다. 혼합액을 37℃에서 30분간 반응시킨 후 UV-Vis spectrophotometer를 사용하여 517 nm 파장에서 흡광도를 분석하였다. 대조군으로는 추출물을 첨가하지 않은 DPPH 용액을 같은 조건에서 흡광도를 분석하여 결과 값을 계산하기 위한 식에 사용하였으며, 흡광도 값을 사용하여 DPPH radical scavenging 활성을 확인하기 위해 다음과 같은 식에 의해 측정하였다.Free radicals are known to cause aging, especially skin aging. To measure the free radical scavenging activity, a 0.2 mM DPPH (2,2-Diphenyl-1-picryl-hydrazyl) solution was prepared using methanol and then mixed with the extracts prepared for each concentration. After the mixture was reacted at 37°C for 30 minutes, absorbance was analyzed at a wavelength of 517 nm using a UV-Vis spectrophotometer. As a control, a DPPH solution without an extract was used in the formula for calculating the result value by analyzing the absorbance under the same conditions, and was measured by the following formula to confirm the DPPH radical scavenging activity using the absorbance value. .

DPPH radical scavenging 활성(%) = [(AbsDPPH - AbsSample)/AbsDPPH] × 100DPPH radical scavenging activity (%) = [(Abs DPPH -Abs Sample )/Abs DPPH ] × 100

여기서 Abssample은 시료 반응액의 흡광도이고, Absblank는 시료만의 흡광도, Abscontrol은 DPPH 용액의 흡광도이다. Here, Abssample is the absorbance of the sample reaction solution, Absblank is the absorbance of only the sample, and Abscontrol is the absorbance of the DPPH solution.

발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 DPPH 제거 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 DPPH 제거 활성이 더 높음을 확인하였다(도 4 참조).As a result of measuring the DPPH removal activity of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, it was confirmed that the DPPH removal activity is higher when using the complex fermentation extract prepared by the fermentation process ( See Figure 4).

2.2 폴리페놀 함량 측정2.2 Measurement of polyphenol content

총 폴리페놀 함량 (total polyphenol content) 측정은 Folin-reagent가 페놀성 화합물에 의해 환원되어 몰리브덴 청색으로 발색되는 원리를 이용하여 함량을 정량하였다. 표준물질은 gallic acid (Sigma)를 사용하여 0-100 ㎍/mL 농도로 제조한 후 시료와 동일한 방법으로 분석하여 얻은 표준 검량선을 기준으로 시료의 폴리페놀 함량을 당량으로 계산하였다. 각 시료의 추출물은 60% 에탄올에 희석한 후 희석한 시료와 Folin-Ciocalteau’s phenol reagent 시약을 혼합하여 실온에서 차광된 상태로 1시간 동안 반응시켰다. 반응 후 96 well plate에 200 μL씩 분주한 후 765 nm에서 흡광도를 측정하고 건조 시료 1 g에서 용출되는 총 폴리페놀의 함량을 gallic acid 기준으로 폴리페놀 함량을 측정하였다. Measurement of total polyphenol content (total polyphenol content) was quantified using the principle that Folin-reagent is reduced by a phenolic compound to develop a molybdenum blue color. The standard was prepared using gallic acid (Sigma) at a concentration of 0-100 µg/mL, and the polyphenol content of the sample was calculated based on the standard calibration curve obtained by analyzing in the same manner as the sample. After extracting the extract of each sample in 60% ethanol, the diluted sample and Folin-Ciocalteau's phenol reagent reagent were mixed and reacted for 1 hour while being shaded at room temperature. After the reaction, 200 μL was dispensed into 96 well plates, and the absorbance was measured at 765 nm, and the total polyphenol content eluted from 1 g of the dried sample was measured based on gallic acid.

발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 총 폴리페놀 함량을 비교한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 총 폴리페놀 함량이 더 높음을 확인하였다(도 4 참조).As a result of comparing the total polyphenol content of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, it is confirmed that the total polyphenol content is higher when using the complex fermentation extract produced by the fermentation process (See FIG. 4).

실시예 4. 항염증 활성 측정Example 4. Measurement of anti-inflammatory activity

3.1 NO(Nitric Oxide) 저해 활성 측정3.1 Measurement of NO (Nitric Oxide) inhibitory activity

본 발명에 따른 복합 발효 추출물에 대하여, 주름 형성의 주요한 원인 중 하나인 염증 반응의 완화 효과를 NO(Nitric Oxide) 생성 억제 효능을 측정하여 평가하였다. For the complex fermentation extract according to the present invention, the effect of alleviating the inflammatory response, which is one of the main causes of wrinkle formation, was evaluated by measuring the effect of inhibiting NO (Nitric Oxide) production.

NO 생성 억제 효능을 측정하기 위해, RAW264.7 세포(mouse monocyte/macrophage-like cell)를 10% FBS가 첨가된 phenol red free DMEM 배지를 이용하여 24-well plate에 5×105 cell/well씩 분주하였다. 시료를 처리하고 48시간 경과 후 배양액을 취하여 Griess reagent와 1:1로 96-well plate에 처리한 후 상온에서 15분간 반응 한 다음 540 nm 파장에서 측정하였다.In order to measure the effect of inhibiting NO production, RAW264.7 cells (mouse monocyte/macrophage-like cells) were added to phenol red free DMEM medium containing 10% FBS at 5×10 5 cells/well in 24-well plates. I was busy. After processing the sample and taking the culture after 48 hours, the sample was treated 1:1 with Griess reagent, and then reacted for 15 minutes at room temperature, and then measured at a wavelength of 540 nm.

농도
(㎍/㎖)
density
(Μg/ml)
NO 생성 저해 활성 (NO production inhibitory activity, %)NO production inhibitory activity (%)
복합 추출물
(complex extract)
Complex extract
(complex extract)
복합 발효 추출물
(Fermented complex extract)
Complex fermentation extract
(Fermented complex extract)
100100 57.46±3.9857.46±3.98 51.57±1.2451.57±1.24 200200 43.60±0.8943.60±0.89 38.00±0.3938.00±0.39 300300 39.36±1.1839.36±1.18 32.36±1.5432.36±1.54 400400 27.77±1.6227.77±1.62 32.59±1.5232.59±1.52 500500 28.13±1.9128.13±1.91 28.70±0.2828.70±0.28

발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 NO 생성 억제 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 다량 사용하는 경우에 NO 생성 억제 활성이 다소 높음을 확인하였다(표 2 및 도 5 참조). As a result of measuring the NO production inhibitory activity of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, the NO production inhibitory activity is somewhat high when a large amount of the complex fermentation extract produced by the fermentation process is used. It was confirmed (see Table 2 and Figure 5).

3.2 Cytokine (TNF-α) 저해 활성 측정3.2 Cytokine (TNF-α) inhibitory activity measurement

본 발명에 따른 복합 발효 추출물에 있어서, 주름의 주요한 원인 중 하나인 염증 반응을 완화시키는 효과가 있는지 평가하기 위하여 염증성 반응 매개 물질인 TNF-α의 농도를 측정하여 복합 발효 추출물 처리 시 저해 활성을 확인하였다.In the complex fermentation extract according to the present invention, in order to evaluate whether there is an effect of alleviating the inflammatory response, which is one of the main causes of wrinkles, the concentration of the inflammatory reaction mediator TNF-α is measured to confirm the inhibitory activity during the treatment of the complex fermentation extract Did.

Raw 264.7 세포를 10% FBS, 1% antibiotics가 첨가된 DMEM 배지를 이용하여 24-well plate에 5×105 cell/well 씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 배양 후 배지를 제거하고 TNF-α 유도를 위해 LPS 1ppm으로 조성한 농도별 추출물 용액을 500 ㎕ 처리한 뒤 24h 반응 시켰다. 이후 배양액을 취하여 TNF-α ELISA kit를 사용하여 TNF-α의 농도를 측정하였다.Raw 264.7 cells were dispensed at 5×10 5 cells/well in 24-well plates using DMEM medium with 10% FBS and 1% antibiotics, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After incubation, the medium was removed and 500 μl of the extract solution according to the concentration composed of 1 ppm of LPS for TNF-α induction was treated and reacted for 24 h. Then, the culture was taken and the concentration of TNF-α was measured using a TNF-α ELISA kit.

농도
(㎍/㎖)
density
(Μg/ml)
TNF-α 분비 저해 활성
(TNF-α secretion inhibitory activity, %)
TNF-α secretion inhibitory activity
(TNF-α secretion inhibitory activity, %)
복합 추출물
(complex extract)
Complex extract
(complex extract)
발효 복합 추출물
(Fermented complex extract)
Fermentation complex extract
(Fermented complex extract)
100100 22.8122.81 45.0345.03 200200 41.8741.87 51.8751.87 300300 54.7254.72 63.2863.28 400400 65.5365.53 67.9467.94 500500 76.8876.88 78.3178.31

발효 과정 없이 제조된 복합 추출물 및 발효 과정에 의해 제조된 복합 발효 추출물의 TNF-α 생성 억제 활성을 측정한 결과, 발효 과정에 의해 제조된 복합 발효 추출물을 사용하는 경우에 TNF-α 생성 억제 활성이 더 높음을 확인하였다(표 3 및 도 6 참조). As a result of measuring the inhibitory activity of TNF-α production of the complex extract prepared without the fermentation process and the complex fermentation extract produced by the fermentation process, the TNF-α production inhibitory activity was observed when using the complex fermentation extract prepared by the fermentation process. It was confirmed that it was higher (see Table 3 and Figure 6).

실시예 4. 미백 활성 측정Example 4. Measurement of whitening activity

4.1 티로시나아제(Tyrosinase) 저해활성 측정4.1 Measurement of tyrosinase inhibitory activity

본 발명에 따른 복합 발효 추출물의 미백 활성을 평가하기 위해, 티로시나아제 저해 활성을 측정하였다. Tyrosinase는 멜라닌을 합성하는 기작에서 작용하여 최종적으로 멜라닌 형성을 유도하는 효소 인자 중 하나이다. To evaluate the whitening activity of the complex fermentation extract according to the present invention, tyrosinase inhibitory activity was measured. Tyrosinase acts on a mechanism for synthesizing melanin and is one of the enzyme factors that induce melanin formation.

B16F10 melanoma를 이용하여 시료의 tyrosinase 저해 활성을 측정하였다. B16F10 melanoma을 6 well plate에 각 well 당 1×104 cells가 되도록 10% FBS가 포함된 각 cell의 배지를 사용하여 2 mL씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 세포의 부착을 확인한 후, 시료를 농도별로 배지를 교환해주고, 1시간 후 100 nM α-MSH 자극제 처리 후, 37℃, 5% CO2 incubator에서 2일 간 배양하였다. 배지를 제거한 후 Triton X-100, 100 mM PMSF를 첨가한 Lysis buffer를 처리하고 10분 동안 15,000 rpm에서 원심분리 하였다. 이 후, 2% N,N-dimethyl formamide와 5 mM L-DOPA를 혼합한 mix buffer를 원심분리한 세포 상등액과 혼합하여 반응시키고 475 nm에서 흡광도를 측정하였다. tyrosinase의 저해 활성은 α-MSH만 처리한 군과 비교하여 백분율로 표시하였다.The tyrosinase inhibitory activity of the sample was measured using B16F10 melanoma. B16F10 melanoma was dispensed in 2 mL by using each cell medium containing 10% FBS in a 6 well plate to be 1×10 4 cells per well, and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After confirming the adhesion of cells, the samples were exchanged for each concentration, and after 1 hour, after 100 nM α-MSH stimulator treatment, the cells were incubated for 2 days at 37°C and 5% CO 2 incubator. After removing the medium, the Lysis buffer to which Triton X-100 and 100 mM PMSF was added was treated and centrifuged at 15,000 rpm for 10 minutes. Thereafter, the mixture buffer mixed with 2% N,N-dimethyl formamide and 5 mM L-DOPA was mixed with the centrifuged cell supernatant to react and absorbance was measured at 475 nm. The inhibitory activity of tyrosinase was expressed as a percentage compared to the group treated with α-MSH only.

농도
(㎍/㎖)
density
(Μg/ml)
티로시나아제(tyrosinase) 저해 활성
(tyrosinase inhibitory activity, %)
Tyrosinase inhibitory activity
(tyrosinase inhibitory activity, %)
복합 추출물
(complex extract)
Complex extract
(complex extract)
발효 복합 추출물
(Fermented complex extract)
Fermentation complex extract
(Fermented complex extract)
100100 22.19±2.9822.19±2.98 23.18±3.5323.18±3.53 200200 29.37±2.0829.37±2.08 38.86±1.5938.86±1.59 300300 43.27±1.8243.27±1.82 45.70±2.6945.70±2.69 400400 45.19±1.6345.19±1.63 50.56±0.8950.56±0.89

복합 발효 추출물의 미백 활성을 측정하기 위해 티로시나아제 저해 활성을 측정한 결과, 사용량에 따라 티로시나아제 저해 활성이 증가하는 것으로 확인하였다. 또한, 동일한 양에서는 발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(표 4 및 도 7 참조).As a result of measuring the tyrosinase inhibitory activity to measure the whitening activity of the complex fermentation extract, it was confirmed that the tyrosinase inhibitory activity increased according to the amount of use. In addition, in the same amount, it was found that the effect of the complex fermentation extract prepared by the fermentation process is higher than that of the complex extract prepared without the fermentation process (see Table 4 and FIG. 7).

4.2 멜라닌(Melanin) 생성 억제활성 측정4.2 Measurement of melanin production inhibitory activity

본 발명에 따른 복합 발효 추출물의 미백 활성을 평가하기 위해, 멜라닌 생성 저해 저해 활성을 측정하였다.In order to evaluate the whitening activity of the complex fermentation extract according to the present invention, melanin production inhibition inhibitory activity was measured.

시료의 멜라닌 생합성에 미치는 영향을 알아보기 위하여 B16F10 melanoma를 6 well plate에 1×104이 되도록 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하였다. 세포의 부착을 확인한 후, 멜라닌 생성을 촉진하기 위하여 10% FBS를 포함된 배지에 농도별로 첨가하여 4시간 배양하고, 이후 100 nM α-MSH 자극제를 처리하여 2 일 간 배양하였다. 배양액을 제거하고 PBS로 세척하고 scrapping하였다. 15,000 rpm에서 20 분간 원심분리 한 후, 상층액을 제거하고 pellet에 10% DMSO가 포함된 1 N NaOH 용액을 첨가하여 80℃에서 1시간 동안 용해하였으며, microplate reader를 이용하여 475 nm에서 흡광도를 측정하였다. 외부자극에 대한 melanoma cell 내 과생성 melanin에 대해 알아보기 위해 자극제로 100 nM α-MSH을 사용하였으며, 실험은 3회 이상 반복 실험하여 시료 무첨가구와 대조하여 그래프로 나타내었다.In order to examine the effect on the biosynthesis of melanin in the sample, B16F10 melanoma was dispensed to 1×10 4 in a 6 well plate and cultured for 24 hours in a 37°C, 5% CO 2 incubator. After confirming the adhesion of the cells, in order to promote melanin production, 10% FBS was added to the medium containing each concentration and cultured for 4 hours, and then treated with 100 nM α-MSH stimulant and cultured for 2 days. The culture was removed, washed with PBS and scrapped. After centrifugation at 15,000 rpm for 20 minutes, the supernatant was removed and 1 N NaOH solution containing 10% DMSO was added to the pellet to dissolve at 80°C for 1 hour, and absorbance was measured at 475 nm using a microplate reader. Did. 100 nM α-MSH was used as a stimulant to find out about over-produced melanin in melanoma cells for external stimulation. The experiment was repeated three or more times, and the graph was compared with the sample-free group.

농도
(㎍/㎖)
density
(Μg/ml)
멜라닌 함량 (Melanin Content, %)Melanin content (Melanin Content, %)
복합 추출물
(complex extract)
Complex extract
(complex extract)
복합 발효 추출물
(Fermented complex extract)
Complex fermentation extract
(Fermented complex extract)
100100 98.04±0.7798.04±0.77 94.56±1.0494.56±1.04 200200 90.49±1.890.49±1.8 79.03±0.8079.03±0.80 300300 76.77±1.4576.77±1.45 74.78±0.9474.78±0.94 400400 61.52±0.9561.52±0.95 59.94±0.8059.94±0.80

복합 발효 추출물의 미백 활성을 측정하기 위해 멜라닌 합성 저해 활성을 측정한 결과, 복합 발효 추출물의 사용량에 따라 멜라닌 합성 저해 활성이 증가하는 것으로 확인하였다. 또한, 동일한 양에서는 발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(도 9).As a result of measuring the melanin synthesis inhibitory activity to measure the whitening activity of the complex fermentation extract, it was confirmed that the melanin synthesis inhibitory activity increases according to the amount of the complex fermentation extract. In addition, in the same amount, it was found that the effect of the complex fermentation extract prepared by the fermentation process is higher than that of the complex extract prepared without the fermentation process (FIG. 9).

실시예 5. 주름 개선 활성 측정Example 5. Measurement of wrinkle improvement activity

본 발명에 따른 복합 발효 추출물의 주름 개선 활성을 평가하기 위해, 콜라겐 생성 활성을 측정하였다.In order to evaluate the wrinkle improvement activity of the complex fermentation extract according to the present invention, collagen production activity was measured.

human fibroblast 세포를 이용하여 시료의 콜라겐 생성에 미치는 영향을 확인하였다. Fibroblast 세포를 Dermal fibroblast growth medium 배지를 이용하여 96-well plate에 well 당 1×104씩 분주하고 37℃, 5% CO2 incubator에서 24시간 배양하여 세포를 부착하였다. 이후 추출물 농도별로 조성한 배지 용액을 처리하고 24 h 후 세포 배양액에 생성된 콜라겐의 농도를 Procollagen Type Ⅰ C-peptide EIA kit를 사용하여 측정하였다.Using human fibroblast cells, the effect on the collagen production of the sample was confirmed. Fibroblast cells were dispensed 1×10 4 per well into a 96-well plate using Dermal fibroblast growth medium medium, and cultured for 24 hours in a 37°C, 5% CO 2 incubator to attach the cells. Subsequently, the medium solution prepared for each extract concentration was treated, and after 24 h, the concentration of collagen generated in the cell culture was measured using a Procollagen Type I C-peptide EIA kit.

발효 과정 없이 제조된 복합 추출물보다는 발효 과정에 의해 제조된 복합 발효 추출물의 효과가 더 높은 것으로 나타났다(도 9).It was found that the effect of the complex fermentation extract prepared by the fermentation process was higher than that of the complex extract prepared without the fermentation process (FIG. 9 ).

실시예 6. 화장료 조성물의 제조Example 6. Preparation of cosmetic composition

하기 표 6에 나타낸 조건(단위, 중량%)으로 화장료 조성물을 제조하였다.A cosmetic composition was prepared under the conditions shown in Table 6 (unit, weight percent).

원료명Raw material name 함량(중량%)Content (% by weight) 정제수Purified water 잔량Balance GlycerinGlycerin 5.0005.000 Sodium hyaluronateSodium hyaluronate 0.0100.010 hydrogel PFKChydrogel PFKC 1.5001.500 Dissolvine NA2-SDissolvine NA2-S 0.0200.020 BetaineBetaine 1.5001.500 carbopol 980carbopol 980 0.2500.250 1.3ㆍBG1.3ㆍBG 1.0001.000 Keltrol FKeltrol F 0.0600.060 CS-165CS-165 1.2001.200 ARLACEL 60ARLACEL 60 0.8000.800 TWEEN 60TWEEN 60 0.8000.800 M.C.TM.C.T 5.0005.000 Lanetto OLanetto O 1.5001.500 Lipex shea softLipex shea soft 0.1000.100 Tocopheryl acetateTocopheryl acetate 0.1000.100 Bees waxBees wax 0.5000.500 Dimethicone 6CSDimethicone 6CS 0.3000.300 TEATEA 0.2500.250 SEPPIPLUS 400SEPPIPLUS 400 0.1500.150 향료Spices 미량a very small amount 복분자, 대두 및 산초의 복합 발효 추출물Complex fermented extract of Bokbunja, Soybean and Sancho 7.0007.000 PhenoxyethanolPhenoxyethanol 0.3000.300 1,2-HEXANEDIOL1,2-HEXANEDIOL 0.4000.400

실시예 7. 추출물이 함유된 약제 제조Example 7. Preparation of the drug containing the extract

하기 표 7에 나타낸 조건(단위, 중량%)으로 약제 조성물을 제조하였다.The pharmaceutical composition was prepared under the conditions (unit, weight%) shown in Table 7 below.

구성 성분Composition 함량 (중량 %)Content (% by weight) 복분자, 대두 및 산초의 복합 발효 추출물Complex fermented extract of Bokbunja, Soybean and Sancho 22 사카린saccharin 0.80.8 Party 25.425.4 글리세린glycerin 88 향미료Spices 0.040.04 에탄올ethanol 44 소르브산Sorbic acid 0.40.4 증류수Distilled water 59.3659.36

실시예 8. 추출물이 함유된 건강 식품 제조Example 8. Preparation of healthy food containing extracts

복분자, 대두 및 산초의 복합 발효 추출물 25 중량부를 과자 반죽에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하였다(표 8 참조).25 parts by weight of the complex fermented extract of bokbunja, soybean and sancho were added to the pastry dough, and bread, cake, cookies, crackers and noodles were prepared using this mixture (see Table 8).

구성 성분Composition 함량 (중량부)Content (parts by weight) 과자 반죽Pastry dough 밀가루flour 100 중량부100 parts by weight 우유milk 10 내지 20 중량부10 to 20 parts by weight 달걀egg 10 내지 20 중량부10 to 20 parts by weight 설탕Sugar 5 내지 10 중량부5 to 10 parts by weight 베이킹파우더Baking powder 0.5 내지 1.5 중량부0.5 to 1.5 parts by weight 베이킹소다Baking soda 0.5 내지 1 중량부0.5 to 1 part by weight 버터butter 5 내지 10 중량부5 to 10 parts by weight 복분자,대두, 산초의 복합 발효 추출물Complex fermentation extract of Bokbunja, Soybean, and Sancho 상기 과자반죽 100 중량부 대비 25 중량부25 parts by weight compared to 100 parts by weight of the pastry dough

본 발명의 단순한 변형 내지 변경은 이 분야의 통상의 지식을 가진 자에 의하여 용이하게 실시될 수 있으며, 이러한 변형이나 변경은 모두 본 발명의 영역에 포함되는 것으로 볼 수 있다.Simple modifications or changes of the present invention can be easily carried out by those skilled in the art, and all such modifications or changes can be considered to be included in the scope of the present invention.

기탁기관명 : 농업생명공학연구원Depository name: Institute for Agricultural Biotechnology

수탁번호 : KACC81067Accession number: KACC81067

수탁일자 : 20171124Date of Deposit: 20171124

Claims (10)

복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 화장료 조성물.
A cosmetic composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient.
제 1항에 있어서, 상기 복분자, 대두 및 산초의 복합 추출물은 복분자, 대두 및 산초를 1 : 1 : 1 의 중량비로 혼합하는 것을 특징으로 하는, 화장료 조성물.
According to claim 1, wherein the complex extract of bokbunja, soybean and sancho, characterized in that the bokbunja, soybean and sancho are mixed in a weight ratio of 1: 1, cosmetic composition.
제 1항에 있어서,
상기 유효성분은 유산균을 사용하여 복분자, 대두 및 산초의 복합 추출물을 발효시켜 제조된 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The active ingredient is produced by fermenting a complex extract of bokbunja, soybean, and sancho using lactic acid bacteria, cosmetic composition.
제 3항에 있어서,
상기 유산균은 Pediococcus pentosaceus B1(KACC 81067BP)인 것을 특징으로 하는, 화장료 조성물.

According to claim 3,
The lactic acid bacteria is Pediococcus pentosaceus B1 (KACC 81067BP), cosmetic composition.

제 3항에 있어서,
상기 발효는 37℃에서 2 내지 7일간 실시하는 것을 특징으로 하는, 화장료 조성물.
According to claim 3,
The fermentation is characterized in that carried out for 2 to 7 days at 37 ℃, cosmetic composition.
제1항에 있어서,
상기 화장료 조성물은 항산화, 항노화, 항염증, 피부 미백 및 주름 개선 용도인 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The cosmetic composition is characterized in that the antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkle improvement purposes, cosmetic composition.
제1항에 있어서,
상기 유효성분은 100 내지 500㎍/mL을 포함하는 것을 특징으로 하는, 화장료 조성물.
According to claim 1,
The active ingredient is characterized in that it contains 100 to 500㎍ / mL, cosmetic composition.
제 1항에 있어서,
상기 화장료 조성물은 화장수, 에센스, 로션, 크림, 팩, 파운데이션, 젤, 연고 및 스프레이로 구성된 군으로부터 선택된 어느 하나의 제형을 갖는 것인 화장료 조성물.
According to claim 1,
The cosmetic composition is a cosmetic composition having any one formulation selected from the group consisting of lotion, essence, lotion, cream, pack, foundation, gel, ointment and spray.
복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화 및 항염증 약학적 조성물.
Antioxidant, anti-aging and anti-inflammatory pharmaceutical composition containing a complex fermented extract of bokbunja, soybean and sancho as an active ingredient.
복분자, 대두 및 산초의 복합 발효 추출물을 유효성분으로 함유하는 항산화, 항노화, 항염증, 피부 미백 및 주름 개선용 건강 식품.A health food for improving antioxidant, anti-aging, anti-inflammatory, skin whitening and wrinkles, which contains a complex fermented extract of bokbunja, soybean, and sancho as an active ingredient.
KR1020180171721A 2018-12-28 2018-12-28 Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use KR20200083712A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020180171721A KR20200083712A (en) 2018-12-28 2018-12-28 Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180171721A KR20200083712A (en) 2018-12-28 2018-12-28 Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use

Publications (1)

Publication Number Publication Date
KR20200083712A true KR20200083712A (en) 2020-07-09

Family

ID=71602253

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180171721A KR20200083712A (en) 2018-12-28 2018-12-28 Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use

Country Status (1)

Country Link
KR (1) KR20200083712A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220077461A (en) 2020-12-02 2022-06-09 천년산초의령 영농조합법인 Sancho lotion manufacturing method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100656241B1 (en) 2004-09-10 2006-12-11 롯데제과주식회사 The extract of Korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition
KR100862610B1 (en) 2006-11-17 2008-10-09 전라북도 고창군 Composition for preventing or treating cardiovascular diseases comprising an extract of rubus coreanum fermentation as active ingredient
KR101056475B1 (en) 2008-10-17 2011-08-11 한국국제대학교 산학협력단 Cosmetic composition for improving atopic skin containing acetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100656241B1 (en) 2004-09-10 2006-12-11 롯데제과주식회사 The extract of Korean fermented soybean with inhibitory effect on hyperlipemia and platelet aggregation, and their composition
KR100862610B1 (en) 2006-11-17 2008-10-09 전라북도 고창군 Composition for preventing or treating cardiovascular diseases comprising an extract of rubus coreanum fermentation as active ingredient
KR101056475B1 (en) 2008-10-17 2011-08-11 한국국제대학교 산학협력단 Cosmetic composition for improving atopic skin containing acetic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220077461A (en) 2020-12-02 2022-06-09 천년산초의령 영농조합법인 Sancho lotion manufacturing method

Similar Documents

Publication Publication Date Title
KR20090083082A (en) Compositions comprising fermentative extract of orchidaceae for improving functions of skin
KR20200083710A (en) Composition containing an fermentation extract of zanthoxylum schinifolium as an active ingredient and its use
KR20220136107A (en) Method for producing fermented product by lactic acid bacteria of Aloe with increased effective component content and postbioics products containing the same
KR20190090363A (en) Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera
KR20110040363A (en) A composition for skin whitening comprising extracts or fractions of eremochloa ophiuroides as an active ingredient
KR101004361B1 (en) The extracts and fractions of Hippophae rhamnoides L.
KR20200083712A (en) Composition containing an mixed fermentation extract of rubus coreanus, soy bean and zanthoxylum schinifolium as an active ingredient and its use
KR102275055B1 (en) Composition comprising scutellaria alpina extract
KR101895572B1 (en) Antioxidant composition comprising uldavioside A
KR101889331B1 (en) A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient
KR102537844B1 (en) Composition with antibacterial, antioxidant, and anti-inflammatory activity containing ingredients converted to kimchi lactic acid bacteria and breast lactic acid bacteria in marigold extract
KR101063351B1 (en) The extracts and fractions of Hippophae rhamnoides L.
KR102342814B1 (en) Composition containing an fermented extract of protaetia brevitarsis seulensis as an active ingredient and manufacturing the same
KR20180024481A (en) Method for preparing apricot extract, the apricot extract prepared therefrom, and skin care or cosmetic composition comprising the apricot extract
KR20120073720A (en) Composition for antiaging comprising the extract of dipterocarpus obtusifolius teijsm. ex miq. as an active ingredient
KR101797843B1 (en) A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient
KR20160091037A (en) Composition comprising gooseberry or glutathione
KR100921971B1 (en) A composition comprising Chamaenerion angustifolium extract as an active ingredient
KR20200101114A (en) Food composition comprising Chrysanthemum zawadskii var extract
KR102453568B1 (en) Composition for moisturizing and anti-inflammation comprising fermented Codium fragile extract fermented by inoculating Bacillus safensis strain
KR102355138B1 (en) Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component
KR101007001B1 (en) The extracts and fractions of Hippophae rhamnoides L.
KR101425560B1 (en) Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient
KR102216618B1 (en) Fermentation method of lactic acid bacteria using artichoke and its use
KR102185438B1 (en) Antioxidant composition containing femented mulberry extract

Legal Events

Date Code Title Description
E601 Decision to refuse application